<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370706</url>
  </required_header>
  <id_info>
    <org_study_id>CPIM447X2104C</org_study_id>
    <secondary_id>2014-003801-14</secondary_id>
    <nct_id>NCT02370706</nct_id>
  </id_info>
  <brief_title>Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis</brief_title>
  <official_title>A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib study with the primary purpose is to estimate the MTD and/or RDE for the&#xD;
      triple combination of PIM447, formerly LGH447, plus ruxolitinib and LEE011 as well as for the&#xD;
      doublets, PIM447 plus ruxolitinib, and LEE011 plus ruxolitinib, in patients with&#xD;
      myelofibrosis (MF). Each regimen will be assessed for safety, tolerability, pharmacokinetics&#xD;
      (PK) and pharmacodynamic effects, and preliminary anti-myelofibrosis activity, including&#xD;
      changes in spleen volume, JAK2V617F allele burden, and hematologic response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2015</start_date>
  <completion_date type="Actual">November 9, 2020</completion_date>
  <primary_completion_date type="Actual">November 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities during the first cycle of study treatment</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>To estimate the maximum tolerated dose and/or recommended dose for expansion for each of the following three treatment arms in patients with myelofibrosis (MF): PIM447 plus ruxolitinib (doublet), LEE011 plus ruxolitinib (doublet), PIM447 plus ruxolitinib and LEE 011 (triple combination).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events/serious adverse events</measure>
    <time_frame>Approximately 27 months (end of study)</time_frame>
    <description>Frequency and severity of adverse events (AEs), serious AEs (SAEs), changes in laboratory values, and electrocardiograms (ECGs), as a measure of safety and tolerability. Assessments consisted of recording all adverse events (AEs) and serious adverse events (SAEs), the regular monitoring of hematology, blood chemistry, urinalysis, and coagulation parameters, as well as electrocardiograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving ≥ 35% reduction in spleen volume by magnetic resonance imaging (MRI) at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ratio of mutant to wild type JAK2 alleles (i.e. allele burden)</measure>
    <time_frame>Approximately 27 months (end of study)</time_frame>
    <description>To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelets, neutrophils, and hemoglobin</measure>
    <time_frame>Approximately 27 months (end of study)</time_frame>
    <description>To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone marrow fibrosis and histomorphology</measure>
    <time_frame>Approximately 27 months (end of study)</time_frame>
    <description>To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine single and multiple dose pharmacokinetics (PK) profiles</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Plasma concentration-time profiles of PIM447, ruxolitinib, and LEE011. PK parameters, including but not limited to Cmax, AUCinf, AUClast, AUCtau, T½, Tmax, accumulation ratio (Racc), CL/F, and Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen volume as measured by MRI from baseline</measure>
    <time_frame>Approximately 27 months (end of study)</time_frame>
    <description>To assess preliminary anti-myelofibrosis activity of PIM447 plus ruxolitinib, LEE011 plus ruxolitinib, and the triple combination PIM447 plus ruxolitinib and LEE011.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PIM447</intervention_name>
    <description>pan-pim inhibitor</description>
    <arm_group_label>Dose Escalation Arm 1</arm_group_label>
    <arm_group_label>Dose Escalation Arm 3</arm_group_label>
    <arm_group_label>Dose Expansion Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>JAK1/JAK2 inhibitor</description>
    <arm_group_label>Dose Escalation Arm 1</arm_group_label>
    <arm_group_label>Dose Escalation Arm 2</arm_group_label>
    <arm_group_label>Dose Escalation Arm 3</arm_group_label>
    <arm_group_label>Dose Expansion Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2</arm_group_label>
    <arm_group_label>Dose Expansion Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>CDK4/6 inhibitor</description>
    <arm_group_label>Dose Escalation Arm 2</arm_group_label>
    <arm_group_label>Dose Escalation Arm 3</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2</arm_group_label>
    <arm_group_label>Dose Expansion Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.&#xD;
&#xD;
          -  Patient must be diagnosed with JAK2V617F-positive primary or secondary MF.&#xD;
&#xD;
          -  Dose-escalation and Expansion parts: Patients with a &lt; 35% reduction in spleen volume&#xD;
             by MRI/CT or &lt; 50% reduction in spleen size by physical exam, with or without&#xD;
             corresponding symptomatic improvement, after at least 6 months of treatment with&#xD;
             single agent ruxolitinib at an optimal dose level in line with the label&#xD;
             recommendations. Expansion parts only: Ruxolitinib-naive patients and patients who&#xD;
             have been previously treated with single agent ruxolitinib and are relapsed and/or&#xD;
             refractory.&#xD;
&#xD;
          -  Patients must have splenomegaly measuring at least 5 cm by MRI at baseline.&#xD;
&#xD;
          -  Have adequate bone marrow function:&#xD;
&#xD;
               -  Platelets ≥ 100,000 mm3 without the assistance of growth factors or platelet&#xD;
                  transfusions&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1500/mm3 without growth factor support within 7&#xD;
                  days prior to testing&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic antineoplastic therapy (including unconjugated therapeutic antibodies, toxin&#xD;
             immunoconjugates, and alpha-interferon) or any experimental therapy within 14 days or&#xD;
             5 half-lives, whichever is shorter, before the first dose of study treatment&#xD;
&#xD;
          -  Major surgery within 2 weeks before the first dose of either study drug.&#xD;
&#xD;
          -  Patients who have had splenic irradiation within 2 weeks prior to Screening or prior&#xD;
             splenectomy.&#xD;
&#xD;
          -  Patients with AML, MDS, or peripheral blasts ≥ 10 %&#xD;
&#xD;
          -  Prior autologous or allogeneic stem cell transplant at any time.&#xD;
&#xD;
          -  Patients who are currently receiving treatment with a prohibited medication that&#xD;
             cannot be discontinued at least one week prior to the start of treatment:&#xD;
&#xD;
               -  substrates of CYP3A4/5, CYP2B6 or CYP2D6 that have a narrow therapeutic window&#xD;
&#xD;
               -  strong inhibitors of CYP3A4/5 or CYP2D6&#xD;
&#xD;
               -  potent inducers of CYP3A4/5 or CYP2D6&#xD;
&#xD;
          -  Serum total bilirubin &gt; 1.5 x upper limit of normal (ULN) except in patients with&#xD;
             Gilbert's syndrome who are excluded if the total bilirubin is &gt; 3.0 x ULN or direct&#xD;
             bilirubin &gt; 1.5 x ULN, or aspartate aminotransferase (AST) (serum glutamic oxaloacetic&#xD;
             transaminase [SGOT]) or ALT (SGPT) &gt; 3 x ULN, except in patients with MF involvement&#xD;
             of the liver who are excluded if AST or ALT &gt; 5 x ULN.&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 x ULN or calculated creatinine clearance &lt; 60 ml/min according&#xD;
             to Cockcroft-Gault equation&#xD;
&#xD;
          -  Electrolyte abnormalities CTCAE grade ≥ 2 (e.g. serum potassium, magnesium and&#xD;
             calcium) unless they can be repleted during screening and are deemed not clinically&#xD;
             significant by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>VIC</city>
        <state>Melbourne</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIM447</keyword>
  <keyword>LGH447</keyword>
  <keyword>PIM inhibitor</keyword>
  <keyword>LEE011</keyword>
  <keyword>CDK 4/6 inhibitor</keyword>
  <keyword>ruxolitinib</keyword>
  <keyword>INC424</keyword>
  <keyword>Jakavi®</keyword>
  <keyword>Jakafi®</keyword>
  <keyword>INCB18424</keyword>
  <keyword>JAK inhibitor</keyword>
  <keyword>myelofibrosis</keyword>
  <keyword>PMF</keyword>
  <keyword>PPV-MF</keyword>
  <keyword>PET-MF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

